Disease progression mechanism in myelodysplastic syndromes: Insight into the role of the microenvironment

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1449-1452

  Ishibashi, Mariko ^a   Tamura, Hideto ^a   Ogata, Kiyoyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

B7 H1 expression; Microenvironment; Myelodysplastic syndromes; Pathogenesis

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CELL POPULATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE COURSE; GENETIC DISORDER; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATASE AND TENSIN HOMOLOG GENE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, CD274; APOPTOSIS; BLAST CRISIS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; INTERFERON-GAMMA; MICE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053984917     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.06.022     Document Type: Article

References (54)

1. Nimer S.D. MDS: a stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease?. Hematology Am Soc Hematol Educ Program 2008, 43-51.
2. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
3. Kibbelaar R.E., van Kamp H., Dreef E.J., de Groot-Swings G., Kluin-Nelemans J.C., Beverstock G.C., et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 1992, 79:1823-1828.
4. Gerritsen W.R., Donohue J., Bauman J., Jhanwar S.C., Kernan N.A., Castro-Malaspina H., et al. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization. Blood 1992, 80:217-224.
5. Anastasi J., Feng J., Le Beau M.M., Larson R.A., Rowley J.D., Vardiman J.W. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 1993, 81:1580-1585.
6. Haase D., Feuring-Buske M., Schafer C., Schoch C., Troff C., Gahn B., et al. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 1997, 11:674-679.
7. Nilsson L., Astrand-Grundstrom I., Anderson K., Arvidsson I., Hokland P., Bryder D., et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 2002, 100:259-267.
8. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
9. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
10. Terpstra W., Ploemacher R.E., Prins A., van Lom K., Pouwels K., Wognum A.W., et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood 1996, 88:1944-1950.
11. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
12. Feuring-Buske M., Hogge D.E. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 2001, 97:3882-3889.
13. Hosen N., Park C.Y., Tatsumi N., Oji Y., Sugiyama H., Gramatzki M., et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007, 104:11008-11013.
14. Benito A.I., Bryant E., Loken M.R., Sale G.E., Nash R.A., John Gass M., et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 2003, 27:425-436.
15. Thanopoulou E., Cashman J., Kakagianne T., Eaves A., Zoumbos N., Eaves C. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004, 103:4285-4293.
16. Ogata K., Satoh C., Tachibana M., Hyodo H., Tamura H., Dan K., et al. Identification and hematopoietic potential of CD45- clonal cells with very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes. Stem Cells 2005, 23:619-630.
17. Frank S.A., Nowak M.A. Problems of somatic mutation and cancer. Bioessays 2004, 26:291-299.
18. Soto A.M., Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm?. Bioessays 2004, 26:1097-1107.
19. Heng H.H., Stevens J.B., Bremer S.W., Ye K.J., Liu G., Ye C.J. The evolutionary mechanism of cancer. J Cell Biochem 2010, 109:1072-1084.
20. Loeb L.A. A mutator phenotype in cancer. Cancer Res 2001, 61:3230-3239.
21. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
22. Epling-Burnette P.K., List A.F. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 2009, 16:70-76.
23. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011, 29:504-515.
24. Watanabe-Okochi N., Kitaura J., Ono R., Harada H., Harada Y., Komeno Y., et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008, 111:4297-4308.
25. Omidvar N., Kogan S., Beurlet S., le Pogam C., Janin A., West R., et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res 2007, 67:11657-11667.
26. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., Loeb L.A. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 2006, 103:18238-18242.
27. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
28. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
29. Mueller M.M., Fusenig N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
30. Udagawa T., Wood M. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol 2010, 10:369-374.
31. Lewis M.P., Lygoe K.A., Nystrom M.L., Anderson W.P., Speight P.M., Marshall J.F., et al. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 2004, 90:822-832.
32. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
33. Maffini M.V., Soto A.M., Calabro J.M., Ucci A.A., Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004, 117:1495-1502.
34. Campbell I., Qiu W., Haviv I. Genetic changes in tumour microenvironments. J Pathol 2011, 223:450-458.
35. Trimboli A.J., Cantemir-Stone C.Z., Li F., Wallace J.A., Merchant A., Creasap N., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
36. Rubin J.B., Gutmann D.H. Neurofibromatosis type 1-a model for nervous system tumour formation?. Nat Rev Cancer 2005, 5:557-564.
37. Bajenaru M.L., Hernandez M.R., Perry A., Zhu Y., Parada L.F., Garbow J.R., et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003, 63:8573-8577.
38. Tennant G.B., Walsh V., Truran L.N., Edwards P., Mills K.I., Burnett A.K. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000, 111:853-862.
39. Tauro S., Hepburn M.D., Bowen D.T., Pippard M.J. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001, 86:1038-1045.
40. Flores-Figueroa E., Gutierrez-Espindola G., Montesinos J.J., Arana-Trejo R.M., Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002, 26:677-686.
41. Marcondes A.M., Mhyre A.J., Stirewalt D.L., Kim S.H., Dinarello C.A., Deeg H.J. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008, 105:2865-2870.
42. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
43. Tamura H., Ogata K., Dong H., Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 2003, 78:321-328.
44. Kondo A., Yamashita T., Tamura H., Zhao W., Tsuji T., Shimizu M., et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010, 116:1124-1131.
45. Koike M., Ishiyama T., Tomoyasu S., Tsuruoka N. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia. Leuk Res 1995, 19:639-644.
46. Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997, 11:2049-2054.
47. Maciejewski J., Selleri C., Anderson S., Young N.S. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995, 85:3183-3190.
48. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
49. Shioi Y., Tamura H., Yokose N., Satoh C., Dan K., Ogata K. Increased apoptosis of circulating T cells in myelodysplastic syndromes. Leuk Res 2007, 31:1641-1648.
50. Azuma T., Yao S., Zhu G., Flies A.S., Flies S.J., Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008, 111:3635-3643.
51. Tamura H., Dan K., Tamada K., Nakamura K., Shioi Y., Hyodo H., et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 2005, 11:5708-5717.
52. Flies D.B., Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007, 30:251-260.
53. Keith T., Araki Y., Ohyagi M., Hasegawa M., Yamamoto K., Kurata M., et al. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 2007, 137:206-215.
54. Della Porta M.G., Malcovati L., Rigolin G.M., Rosti V., Bonetti E., Travaglino E., et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia 2008, 22:530-537.